A role for fMRI in optimizing CNS drug development
- PMID: 16604100
- DOI: 10.1038/nrd2027
A role for fMRI in optimizing CNS drug development
Abstract
Drug development today needs to balance agility, speed and risk in defining the probability of success for molecules, mechanisms and therapeutic concepts. New techniques in functional magnetic resonance imaging (fMRI) promise to be part of a sequence that could transform drug development for disorders of the central nervous system (CNS) by examining brain systems and their functional activation dynamically. The brain is complex and multiple transmitters and intersecting brain circuits are implicated in many CNS disorders. CNS therapeutics are designed against specific CNS targets, many of which are unprecedented. The challenge is to reveal the functional consequences of these interactions to assess therapeutic potential. fMRI can help optimize CNS drug discovery by providing a key metric that can increase confidence in early decision-making, thereby improving success rates and reducing risk, development times and costs of drug development.
Similar articles
-
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.Pharmacol Ther. 2004 Oct;104(1):29-45. doi: 10.1016/j.pharmthera.2004.08.001. Pharmacol Ther. 2004. PMID: 15500907 Review.
-
Animal models of depression: challenges from a drug development perspective.Behav Pharmacol. 2003 Sep;14(5-6):385-90. doi: 10.1097/01.fbp.0000087738.21047.91. Behav Pharmacol. 2003. PMID: 14501252 Review.
-
The role of molecular imaging in drug discovery and development.Clin Pharmacol Ther. 2008 Feb;83(2):349-53. doi: 10.1038/sj.clpt.6100467. Epub 2008 Jan 2. Clin Pharmacol Ther. 2008. PMID: 18167503 Review.
-
Integration of mass spectrometry into early-phase discovery and development of central nervous system agents.J Mass Spectrom. 2001 Nov;36(11):1211-9. doi: 10.1002/jms.227. J Mass Spectrom. 2001. PMID: 11747117
-
Clinical trials in CNS--SMi's eighth annual conference.IDrugs. 2010 Feb;13(2):66-9. IDrugs. 2010. PMID: 20127552
Cited by
-
Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.Psychopharmacology (Berl). 2021 May;238(5):1255-1263. doi: 10.1007/s00213-019-05427-5. Epub 2020 Jan 4. Psychopharmacology (Berl). 2021. PMID: 31900526 Review.
-
Cellular resolution functional imaging in behaving rats using voluntary head restraint.Neuron. 2013 Oct 16;80(2):371-84. doi: 10.1016/j.neuron.2013.08.002. Epub 2013 Sep 19. Neuron. 2013. PMID: 24055015 Free PMC article.
-
The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence.Brain Neurosci Adv. 2018 Nov 7;2:2398212818804030. doi: 10.1177/2398212818804030. eCollection 2018 Jan-Dec. Brain Neurosci Adv. 2018. PMID: 32166151 Free PMC article. Review.
-
Frontal midline theta reflects anxiety and cognitive control: meta-analytic evidence.J Physiol Paris. 2015 Feb-Jun;109(1-3):3-15. doi: 10.1016/j.jphysparis.2014.04.003. Epub 2014 Apr 29. J Physiol Paris. 2015. PMID: 24787485 Free PMC article.
-
In vivo imaging of the neurovascular unit in CNS disease.Intravital. 2012 Dec 1;1(2):87-94. doi: 10.4161/intv.22214. Intravital. 2012. PMID: 25197615 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical